AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32665120 — intervention group
Group type: COMPARATOR
Intervention: Natural enamel opposing polished zirconia crowns (NE-PZ-PM)
Number of subjects: 14
Study 32665120 — intervention group
Group type: COMPARATOR
Intervention: Natural enamel opposing glazed zirconia crowns (NE-GZ-PM)
Number of subjects: 14
Study 32665120 — intervention group
Group type: COMPARATOR
Intervention: Natural enamel opposing natural enamel (NE-PM)
Number of subjects: 14
Study 33266318 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation
Number of subjects: 0
Study 34417112 — intervention group
Group type: EXPERIMENTAL
Intervention: CheReCunJin decoction only
Number of subjects: 70
Study 34417112 — intervention group
Group type: EXPERIMENTAL
Intervention: CheReCunJin decoction combined with hydroxychloroquine
Number of subjects: 70
Study 34247392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic precursor
Number of subjects: 29
Study 34247392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic antagonist
Number of subjects: 29
Study 34247392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 35615945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient photographs during simulated handoffs
Number of subjects: 40
Study 35615945 — intervention group
Group type: COMPARATOR
Intervention: Simulated handoffs without photographs
Number of subjects: 40
Study 33736678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand and foot acupuncture with twelve needles
Number of subjects: 208
Study 33736678 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 208
Study 32693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Refutation message
Number of subjects: 1591
Study 32693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic + factual message
Number of subjects: 1591
Study 32693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic + factual + refutation message
Number of subjects: 1591
Study 32693322 — intervention group
Group type: COMPARATOR
Intervention: Basic description of DCR
Number of subjects: 1591
Study 32693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual message alone
Number of subjects: 1591
Study 32693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic message alone
Number of subjects: 1591
Study 35422003 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported instant messaging service (IMS) intervention in addition to standard diabetes therapy for 7 months
Number of subjects: 205
Study 35422003 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes therapy
Number of subjects: 205
Study 33827843 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 128
Study 33827843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 32234462 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 464
Study 32234462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 35272093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early gestational diabetes diagnosed at <20 weeks gestation
Number of subjects: 119
Study 35272093 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetes diagnosed by routine screening at 24-28 weeks gestation
Number of subjects: 119
Study 33762244 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS + MCE
Number of subjects: 140
Study 33762244 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS + MCE
Number of subjects: 140
Study 33762244 — intervention group
Group type: COMPARATOR
Intervention: Active rTMS
Number of subjects: 140
Study 33762244 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 140
Study 33060086 — intervention group
Group type: EXPERIMENTAL
Intervention: It Takes Two intervention
Number of subjects: 100
Study 33060086 — intervention group
Group type: COMPARATOR
Intervention: Control (HIV prevention information only)
Number of subjects: 100
Study 35950781 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10-mg tablets)
Number of subjects: 67
Study 35950781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 35950781 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 67
Study 34050738 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher platelet number PRP injections
Number of subjects: 8
Study 34050738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower platelet number PRP injections
Number of subjects: 8
Study 34050738 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 8
Study 32928216 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg/d)
Number of subjects: 80
Study 32928216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 80
Study 36163948 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan (1,080 mg subcutaneously twice weekly)
Number of subjects: 80
Study 36163948 — intervention group
Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 80
Study 36163948 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 80
Study 34712981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate (BMA) injection
Number of subjects: 22
Study 34712981 — intervention group
Group type: COMPARATOR
Intervention: Cortisone injection
Number of subjects: 22
Study 34712981 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BMA and Cortisone
Number of subjects: 22
Study 36057629 — intervention group
Group type: COMPARATOR
Intervention: Daily supplementation with 250 ml fruit smoothie including a variety of fruits (apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, blackcurrant) for 16 weeks.
Number of subjects: 302
Study 36057629 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without added supplementation.
Number of subjects: 302
Study 36057629 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 250 ml fruit smoothie.
Number of subjects: 302
Study 32532831 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT2B10 genetic score of 2
Number of subjects: 916
Study 32532831 — intervention group
Group type: COMPARATOR
Intervention: UGT2B10 genetic score of 0
Number of subjects: 916
Study 32532831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 activity ratio increase of 0.1
Number of subjects: 916
Study 32532831 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT2B10 genotype adjustment
Number of subjects: 916
Study 35525396 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+Soccer (DS)
Number of subjects: 39
Study 35525396 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+Running (DR)
Number of subjects: 39
Study 35525396 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 39
Study 33771279 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated exposure therapy (COPE; Back et al., 2015)
Number of subjects: 119
Study 33771279 — intervention group
Group type: COMPARATOR
Intervention: Integrated coping skills therapy (Seeking Safety; Najavits, 2002)
Number of subjects: 119
Study 32673060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days)
Number of subjects: 491
Study 32673060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 32673060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 491
Study 36400822 — intervention group
Group type: EXPERIMENTAL
Intervention: Grain production systems with species diversification
Number of subjects: 0
Study 36400822 — intervention group
Group type: COMPARATOR
Intervention: Corn-soybean rotation without species diversification
Number of subjects: 0
Study 34522910 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive remediation programme (brain games) for 8 weeks
Number of subjects: 372
Study 34522910 — intervention group
Group type: COMPARATOR
Intervention: Low complexity computer games and health education classes (control group)
Number of subjects: 372
Study 32011032 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42
Study 32011032 — intervention group
Group type: COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42
Study 32011032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 34684356 — intervention group
Group type: EXPERIMENTAL
Intervention: Two enriched eggs per day for 4 months
Number of subjects: 99
Study 34684356 — intervention group
Group type: COMPARATOR
Intervention: Two standard eggs per day for 4 months
Number of subjects: 99
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐NP (1 mg/kg diet)
Number of subjects: 180
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn‐NP (10 mg/kg diet)
Number of subjects: 180
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Se/Zn‐NP (1 mg/kg Se‐NP and 10 mg/kg Zn‐NP)
Number of subjects: 180
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Se/Zn‐NP
Number of subjects: 180
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐NP, Zn‐NP, Se/Zn‐NP
Number of subjects: 180
Study 33569732 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐NP, Zn‐NP
Number of subjects: 180
Study 33569732 — intervention group
Group type: COMPARATOR
Intervention: CG (0 Se‐NP and Zn‐NP)
Number of subjects: 180
Study 32114326 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Nutrition Facts Label (NFL)
Number of subjects: 0
Study 32114326 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention about added sugars
Number of subjects: 0
Study 33666125 — intervention group
Group type: EXPERIMENTAL
Intervention: OsseoSpeed® TX (test)
Number of subjects: 92
Study 33666125 — intervention group
Group type: COMPARATOR
Intervention: OsseoSpeed® (control)
Number of subjects: 92
Study 34265008 — intervention group
Group type: EXPERIMENTAL
Intervention: Not working (employment status)
Number of subjects: 2609
Study 34265008 — intervention group
Group type: EXPERIMENTAL
Intervention: Not living with spouse (living status)
Number of subjects: 2609
Study 34265008 — intervention group
Group type: COMPARATOR
Intervention: Educational attainment
Number of subjects: 2609
Study 34265008 — intervention group
Group type: COMPARATOR
Intervention: Equivalent household expenditure (EHE)
Number of subjects: 2609
Study 36053813 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of RT-CGM
Number of subjects: 61
Study 36053813 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of RT-CGM with a 3-month interval
Number of subjects: 61
Study 36053813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 34449461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive occupational health coaching for 12 weeks
Number of subjects: 63
Study 34449461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 32172334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (cet)
Number of subjects: 270
Study 32172334 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of metastases
Number of subjects: 270
Study 32172334 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (bev)
Number of subjects: 270
Study 35838535 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline + lidocaine detection group (AD group)
Number of subjects: 300
Study 35838535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton bud detection group (CD group)
Number of subjects: 300
Study 35838535 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 34314737 — intervention group
Group type: EXPERIMENTAL
Intervention: Border closure
Number of subjects: 69
Study 34314737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarantine of travelers
Number of subjects: 69
Study 34314737 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at departure and/or arrival
Number of subjects: 69
Study 34314737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of public health measures
Number of subjects: 69
Study 34314737 — intervention group
Group type: EXPERIMENTAL
Intervention: Public support for travel restrictions
Number of subjects: 69
Study 33017417 — intervention group
Group type: EXPERIMENTAL
Intervention: No scarring at baseline
Number of subjects: 1496
Study 33017417 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarring at baseline
Number of subjects: 1496
Study 36442220 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual implantation (group 1)
Number of subjects: 50
Study 36442220 — intervention group
Group type: COMPARATOR
Intervention: Randomized implantation (group 2)
Number of subjects: 50
Study 32971307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota features (specifically 25 bacteria features including 9 orders and 16 families) analyzed in the discovery sample.
Number of subjects: 426824
Study 32971307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridiales and Lachnospiraceae (child taxon of Clostridiales)
Number of subjects: 426824
Study 33052762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Informed Intervention (MII) consisting of mindfulness training with cognitive, behavioral, and psychoeducational components, delivered in four 2-hour sessions weekly
Number of subjects: 56
Study 33052762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Informed Intervention (MII)
Number of subjects: 56
Study 32585738 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day milnacipran
Number of subjects: 49
Study 32585738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 34231274 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on treatment adherence provided by nurses, repeated in 2nd, 4th, 8th, and 12th weeks
Number of subjects: 58
Study 34231274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 58
Study 34231274 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on treatment adherence
Number of subjects: 58
Study 34120358 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 0
Study 34120358 — intervention group
Group type: COMPARATOR
Intervention: DPW
Number of subjects: 0
Study 34120358 — intervention group
Group type: COMPARATOR
Intervention: AUD
Number of subjects: 0
Study 33051646 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0
Study 33051646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35190217 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mobilization
Number of subjects: 64
Study 35190217 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilization with place and hold
Number of subjects: 64
Study 34117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1312
Study 34117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1312
Study 34117082 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese
Number of subjects: 1312
Study 34117082 — intervention group
Group type: COMPARATOR
Intervention: Overweight vs Normal Weight
Number of subjects: 1312
Study 34117082 — intervention group
Group type: COMPARATOR
Intervention: Obese vs Normal Weight
Number of subjects: 1312
Study 32683460 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner wires
Number of subjects: 122
Study 32683460 — intervention group
Group type: COMPARATOR
Intervention: Herbert screw
Number of subjects: 122
Study 35599043 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided surgical templates in association with mandibular distraction osteogenesis
Number of subjects: 12
Study 35599043 — intervention group
Group type: COMPARATOR
Intervention: Conventional distraction osteogenesis
Number of subjects: 12
Study 35599043 — intervention group
Group type: EXPERIMENTAL
Intervention: Post distraction osteogenesis
Number of subjects: 12
Study 33545674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold (NSS) implantation
Number of subjects: 19
Study 35286511 — intervention group
Group type: EXPERIMENTAL
Intervention: No-fixation (NF) group
Number of subjects: 100
Study 35286511 — intervention group
Group type: COMPARATOR
Intervention: Fixed mesh group
Number of subjects: 100
Study 34404029 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA availability in hospitals treating APL
Number of subjects: 49
Study 34404029 — intervention group
Group type: COMPARATOR
Intervention: ATRA availability in referring centers
Number of subjects: 49
Study 34404029 — intervention group
Group type: COMPARATOR
Intervention: Overall ATRA availability in hospitals
Number of subjects: 49
Study 34404029 — intervention group
Group type: COMPARATOR
Intervention: Hospital size and academic status influence on ATRA availability
Number of subjects: 49
Study 32861271 — intervention group
Group type: EXPERIMENTAL
Intervention: cEEG plus ANSeR (algorithm group)
Number of subjects: 264
Study 32861271 — intervention group
Group type: COMPARATOR
Intervention: cEEG monitoring alone (non-algorithm group)
Number of subjects: 264
Study 36343044 — intervention group
Group type: EXPERIMENTAL
Intervention: MT10107
Number of subjects: 30
Study 36343044 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 30
Study 32213037 — intervention group
Group type: EXPERIMENTAL
Intervention: PillCam Crohn's score
Number of subjects: 41
Study 32213037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lewis inflammatory score
Number of subjects: 41
Study 34503909 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged percutaneous coronary intervention (SPCI)
Number of subjects: 903
Study 34503909 — intervention group
Group type: EXPERIMENTAL
Intervention: SPCI in patients with 3VD
Number of subjects: 903
Study 34503909 — intervention group
Group type: EXPERIMENTAL
Intervention: SPCI in patients with LM
Number of subjects: 903
Study 33030989 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Fit program plus Prevention services
Number of subjects: 436
Study 33030989 — intervention group
Group type: COMPARATOR
Intervention: Control group (only Prevention services)
Number of subjects: 436
Study 33545336 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (BPO) treatment
Number of subjects: 100
Study 33545336 — intervention group
Group type: COMPARATOR
Intervention: Control group (soap preparation)
Number of subjects: 100
Study 36254907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistin (NC) along with intravenous (IV) antibiotics
Number of subjects: 98
Study 36254907 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline (NS) along with intravenous (IV) antibiotics
Number of subjects: 98
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: African Buffalo Optimization algorithm (ABO)
Number of subjects: 15
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Extremal Optimization (IEO)
Number of subjects: 15
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐Induced Max‐Min Ant Colony Optimization (MIMM‐ACO)
Number of subjects: 15
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Max‐Min Ant System (MMAS)
Number of subjects: 15
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Genetic Ant System (CGAS)
Number of subjects: 15
Study 33986793 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Insertion Algorithm (RAI)
Number of subjects: 15
Study 32586643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast‐helical mode (FHM)
Number of subjects: 96
Study 32586643 — intervention group
Group type: COMPARATOR
Intervention: Two-axial mode (TAM)
Number of subjects: 96
Study 35421369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg or 200 mg twice daily for 12 weeks)
Number of subjects: 120
Study 35421369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35421369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 120
Study 34607598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis
Number of subjects: 20
Study 34607598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32380239 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD) after one night
Number of subjects: 50
Study 32380239 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD) after two nights
Number of subjects: 50
Study 32380239 — intervention group
Group type: COMPARATOR
Intervention: Full rest (baseline condition)
Number of subjects: 50
Study 35245227 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankincense essential oil applied to the soles of the feet twice a day for 2 days before, during, and 2 days after chemotherapy.
Number of subjects: 70
Study 35245227 — intervention group
Group type: COMPARATOR
Intervention: Control (carrier oil without frankincense) applied to the soles of the feet twice a day for 2 days before, during, and 2 days after chemotherapy.
Number of subjects: 70
Study 33694150 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester maternal serum ProBNP levels
Number of subjects: 64
Study 33694150 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 64
Study 33694150 — intervention group
Group type: EXPERIMENTAL
Intervention: ProBNP cut-off level of 50.93
Number of subjects: 64
Study 36193498 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (HbA1c<6.5%)
Number of subjects: 93
Study 36193498 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (6.5%≤HbA1c≤8.5%)
Number of subjects: 93
Study 36193498 — intervention group
Group type: COMPARATOR
Intervention: Group C (HbA1c>8.5%)
Number of subjects: 93
Study 36193498 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 93
Study 36193498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac function measures
Number of subjects: 93
Study 34807656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 167
Study 34807656 — intervention group
Group type: COMPARATOR
Intervention: Art therapy (ART)
Number of subjects: 167
Study 32590653 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with lidocaine and adrenaline (WALANT)
Number of subjects: 102